Philadelphia Pharmaceuticals PLC develops, manufactures, and markets human pharmaceutical products, cosmetics, and medical devices of various therapeutic categories in Jordan.
The last earnings update was 26 days ago.
Discounted Cash Flow Calculation for ASE:PHIL using Dividend Discount Model Model
The calculations below outline how an intrinsic value for
is arrived at by discounting future dividends to their present value. This
approach is used for finance firms where free cash flow is difficult to estimate
(e.g. Banks/ Insurance firms).
If the firm does not pay the majority of its earnings out as a dividend this
method will often arrive at a value significantly lower than the share price.
The current share price of
is above its future cash flow value.
Often investors are willing to pay a
for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Philadelphia Pharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Philadelphia Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Philadelphia Pharmaceuticals's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Philadelphia Pharmaceuticals's earnings growth to the market average as no estimate data is available.
Unable to compare Philadelphia Pharmaceuticals's revenue growth to the market average as no estimate data is available.
Unable to determine if Philadelphia Pharmaceuticals is high growth as no earnings estimate data is available.
Unable to determine if Philadelphia Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Philadelphia Pharmaceuticals's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
4/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Philadelphia Pharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
Philadelphia Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Philadelphia Pharmaceuticals has no long term commitments.
This treemap shows a more detailed breakdown of
Philadelphia Pharmaceuticals's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 6.2x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Kayed Gazi Abdullah Al-Shaabani is Chief Executive Officer at Philadelphia Pharmaceutical Company since 2018 and is its Vice chairman. Mr. Al-Shaabani serves as General Manager for Etihad Brokerage. Mr. Al-Shaabani has over 22 years a career background in Financing and Financial Markets and 26 years of experience in Management and finance. He holds a BSC in Commerce.
Insufficient data for Kayed Gazi to compare compensation growth.
Insufficient data for Kayed Gazi to establish whether their remuneration is reasonable compared to companies of similar size in Jordan.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Philadelphia Pharmaceuticals management team is about average.
Khader Mohammed Jarwan
GM & Director
Kayed Gazi Al-Shaabani
Vice Chairman & CEO
Deputy General Manager of Sales
Board of Directors
Munther Ahmad Hussein
Khader Mohammed Jarwan
GM & Director
Kayed Gazi Al-Shaabani
Vice Chairman & CEO
Ahmad Ismail Syan
Gabriel Georges. Kalisse
Mohamed Ismail Syan
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Philadelphia Pharmaceuticals PLC develops, manufactures, and markets human pharmaceutical products, cosmetics, and medical devices of various therapeutic categories in Jordan. The company offers products for skin related disorders, including anti-lice and scabicides preparations, antiseptics and disinfectants, bleaching and hyperpigmentation disorders preparations, emollients and protectives, keratolytics/topical psoriasis treatment preparations, and skin healing agents, as well as agents for dermatitis; and topical acne preparations, anti-pruritic, anti-viral, plain antifungals and anti-infective, plain steroids, steroids with antifungal/anti-infective combination, and skin recoloring products. It also provides products for women health, such as vaginal antifungals, alkalinizing and cleansing agents, antimicrobials, germicidal fungicidal, antiseptics and hemostatic, and vaginal progesterone; and products in the areas of alimentary, gastrointestinal system, anti-inflammatory, analgesic, antipyretic, dental-oropharyngeal, hair care, local anesthetics, and respiratory system, as well as supplements and health care-OTC products. The company also exports its products to 16 countries in the Middle East and North Africa region. Philadelphia Pharmaceuticals PLC was founded in 1993 and is headquartered in Amman, Jordan.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.